Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast Cancer

MONDAY, April 20, 2020 -- The U.S. Food and Drug Administration announced Friday the approval of Tukysa (tucatinib) in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news